85 related articles for article (PubMed ID: 11156218)
21. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
[TBL] [Abstract][Full Text] [Related]
22. Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion.
Toh U; Fujii T; Seki N; Niiya F; Shirouzu K; Yamana H
Cancer Immunol Immunother; 2006 Oct; 55(10):1219-27. PubMed ID: 16362409
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma.
Homma S; Matai K; Irie M; Ohno T; Kufe D; Toda G
J Gastroenterol; 2003; 38(10):989-94. PubMed ID: 14614608
[TBL] [Abstract][Full Text] [Related]
24. [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer].
Toh U; Fujii T; Mishima M; Imaizumi T; Koga A; Yano S; Shirouzu K; Yahara T; Yamana H
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1931-3. PubMed ID: 18219856
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
Bouet-Toussaint F; Patard JJ; Gervais A; Genetet N; de la Pintière CT; Rioux-Leclercq N; Toutirais O; Thirouard AS; Ramée MP; Catros-Quemener V
Cancer Immunol Immunother; 2003 Nov; 52(11):699-707. PubMed ID: 12879292
[TBL] [Abstract][Full Text] [Related]
26. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.
Spaner DE; Hammond C; Mena J; Foden C; Deabreu A
Cancer Immunol Immunother; 2005 Jul; 54(7):635-46. PubMed ID: 15918075
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
[TBL] [Abstract][Full Text] [Related]
30. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.
Carbone DP; Ciernik IF; Kelley MJ; Smith MC; Nadaf S; Kavanaugh D; Maher VE; Stipanov M; Contois D; Johnson BE; Pendleton CD; Seifert B; Carter C; Read EJ; Greenblatt J; Top LE; Kelsey MI; Minna JD; Berzofsky JA
J Clin Oncol; 2005 Aug; 23(22):5099-107. PubMed ID: 15983396
[TBL] [Abstract][Full Text] [Related]
31. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
32. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
Mazzolini G; Alfaro C; Sangro B; Feijoó E; Ruiz J; Benito A; Tirapu I; Arina A; Sola J; Herraiz M; Lucena F; Olagüe C; Subtil J; Quiroga J; Herrero I; Sádaba B; Bendandi M; Qian C; Prieto J; Melero I
J Clin Oncol; 2005 Feb; 23(5):999-1010. PubMed ID: 15598979
[TBL] [Abstract][Full Text] [Related]
34. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
36. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
37. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
38. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
39. [Effects of recombinant interleukin-2 on several characteristics of functional activity of lymphocytes from the lymph nodes regional to tumor and mononuclear cells of peripheral blood in cancer patients].
Semenova-Kobzar' RA; Kushko LIa; Iakhimovich LV; Protsyk VS; Tolstopiatov BA; Konovalenko VF; Berezhnaia NM
Eksp Onkol; 1990; 12(4):53-7. PubMed ID: 2379489
[TBL] [Abstract][Full Text] [Related]
40. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
